Featured News - Current News - Archived News - News Categories
Lanreotide Confers Multiple Benefits In Acromegaly Patients
Mon, Jun 15th 2009 05:05 pm
 |
 |
Lanreotide Confers Multiple Benefits In Acromegaly Patients13 Jun 2009
WASHINGTON D.C. - Most patients with acromegaly who are switched to
the long-acting somatostatin analogue lanreotide (SomatulineR Depot)
injection from initial treatment with octreotide cite a preference for
lanreotide as their future therapy, according to data released here at
the 91st Annual Meeting of the Endocrine Society (ENDO 09).
The results, from the multicenter Assessment of the Ability of Subjects
With Acromegaly or Their Partners to Administer Somatuline Autogel
(SALSA) study, also demonstrate good efficacy and tolerability with
self- or partner-inject lanreotide.
"The main message to clinicians is that patients with acromegaly can
either inject themselves with the medication or have a family member
rather than a health care professional do it for it for them, thereby
avoiding monthly trips to the doctor's office," said SALSA principal
investigator Roberto Salvatori, MD, associate professor of medicine at
Johns Hopkins University in Baltimore.
Dr. Salvatori and co-workers tested the convenience, safety, and
efficacy of self- or partner-administration of lanreotide in 59
acromegalic patients who were switched directly from lanreotide and in
other patients who were treatment-naïve or not currently on lanreotide.
The study's primary endpoint was the percentage of patients/partners
competent to self- or partner-administer lanreotide at study completion
as assessed by the health care professional. .
Overall, 41 patients said they were able to correctly self-inject, and
the other 18 were able to correctly partner- inject lanreotide.
Self- or partner -administration of lanreotide was associated with
insulin growth factor (IGF)-1 and growth hormone (GH ) control in many
patients with acromegaly (73.1% of switch and 30.4% of other patients)
at the end of the trial.
Self- or partner -administration of lanreotide was associated with
insulin growth factor (IGF)-1 and growth hormone (GH ) control in many
patients with acromegaly (73.1% of switch and 30.4% of other patients)
at the end of the trial.
Self- or partner-administration of lanreotide was generally well
tolerated, and fewer lanreotide-treated patients described their
injections as painful.
Eight one percent of patients said they preferred lanreotide for future
use, 13 percent favored octreotide, and six percent voiced no
preference.
Dr. Salvatori said that about 50 to 60% of patients with active
acromegaly respond to the somatostatin analogue class of medications.
The ideal patient, he added, is a patient who has either failed surgery
(not cured) or for whom surgery would be risky (coexisting diseases) as
well as the patient who is unlikely to be cured (tumors with extension
in nonoperable areas but without compression of the vision pathways).
Acromegaly results from an excessive production of growth hormone,
which produces an enlargement and overgrowth of many organs, bones, and
soft tissues as well as metabolic and biochemical changes. About three
to four out of every million adults will develop the condition each
year.
The disorder is often misdiagnosed because of its wide range of
symptoms and their slow onset, and it may take in some cases take up to
ten years to establish a correct diagnosis. Unless treated, acromegaly
can lead to severe sequelae, including the onset of type 2 diabetes,
hypertension, arthritis, an increased risk of cardiovascular disease,
and colon cancer.
Written by Jill Stain
Jill Stein is a Paris-based freelance medical writer.
jillstein03(at)gmail.com
Copyright: Medical News Today
Not to be reproduced without permission of Medical News Today
Article URL: http://www.medicalnewstoday.com/articles/153791.php
Main News Category: Endocrinology
Also Appears In: Pharma Industry / Biotech Industry, Clinical Trials / Drug Trials,
|
|
Any medical information published on this website is not intended as
a substitute for informed medical advice and you should not take any
action before consulting with a health care professional. For more
information, please read our terms and conditions.
Save time! Get the latest medical news headlines for your specialist area, in a weekly newsletter e-mail. See http://www.medicalnewstoday.com/newsletters.php for details.
|
|
|
Send your press releases to
AntiSpambotMailto('145|147|134|148|148|147|134|141|134|130|148|134|97|142|134|133|138|132|130|141|143|134|152|148|149|144|133|130|154|79|132|144|142')pressrelease@medicalnewstoday.com |
|
